Psyched Wellness has carried out a neurobehavioral study evaluating the safety and efficacy of its Amanita Muscaria extract – AME-1.
Beckley Psytech has announced the successful completion of its Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT.
Origin Therapeutics’ portfolio company, Xpira Pharmaceuticals, has received FDA approval for its Psilocybin Trial IND Application.
A new study by Johns Hopkins Medicine researchers compared psychedelic experiences with near-death experiences that were not drug-related, finding notable similarities in people’s attitudes toward death.
A new study conducted by Columbia University Mailman School of Public Health and Columbia University Irving Medical Center estimates that over 5.5 million people in the US used hallucinogens...
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
A Phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of DMT will further research into the compound’s therapeutic potential.